SequelSEC

Artiva Biotherapeutics, Inc. ARTV

Biological Products, (No Diagnostic Substances) · CIK 0001817241 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Artiva Biotherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Artiva Biotherapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
RevenueUnavailable$0$0$0$251.00K$2.35M$26.66M$3.50M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailable-$18.27M-$18.34M-$16.19M-$14.49M-$11.97M$10.81M-$11.82M
Net incomeUnavailable-$16.10M-$17.47M-$17.84M-$13.96M-$12.00M$11.28M-$11.28M
Research & developmentUnavailable$13.32M$13.52M$12.33M$11.16M$11.15M$13.06M$11.26M
Weighted-average diluted sharesUnavailableUnavailableshares 18.90MUnavailableUnavailableUnavailableshares 6.97MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailable$-0.92$-22.00$-17.24Unavailable$1.62$-14.09
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$4.95M$4.81M$3.86M$3.59M$3.17M$2.78M$4.06M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Artiva Biotherapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Cash & equivalents$26.70M$40.24M$55.88M$34.25M$48.20M$53.50M$65.88M$53.70M
Total assets$130.94M$209.58M$225.60M$75.91MUnavailable$105.11MUnavailableUnavailable
Current assets$112.67M$188.63M$150.56M$49.75MUnavailable$79.82MUnavailableUnavailable
Total liabilities$20.97M$22.94M$24.60M$50.60MUnavailable$50.72MUnavailableUnavailable
Current liabilities$13.09M$12.25M$13.29M$10.83MUnavailable$12.23MUnavailableUnavailable
Total equity incl. NCI$109.97M$186.64M$201.00M-$191.10M-$174.67M-$162.02M-$151.45M-$164.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$0$569.00K$569.00KUnavailable$1.03MUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$355.00K$1.12M$1.22M$823.00KUnavailable$614.00KUnavailableUnavailable

Cash flow

Artiva Biotherapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Operating cash flowUnavailable-$14.65M-$11.61M-$13.68M-$15.09M-$10.68M-$10.75MUnavailable
Capital expendituresUnavailable$64.00K$96.00K$464.00K$18.00K$636.00K$179.00KUnavailable
Investing cash flowUnavailable-$966.00K-$130.63M$1.35M$9.78M-$2.67M-$493.00KUnavailable
Financing cash flowUnavailable-$30.00K$163.87MUnavailableUnavailable$962.00K$23.43MUnavailable
Net change in cashUnavailable-$15.65M$21.63M-$13.95M-$5.30M-$12.38M$12.19MUnavailable
Stock-based compensationUnavailable$2.18M$1.91M$1.48M$1.41M$1.39M$1.37MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$614.00K$627.00K$603.00K$587.00K$594.00K$556.00KUnavailable

Derived

Artiva Biotherapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Free cash flowUnavailable-$14.71M-$11.71M-$14.15M-$15.10M-$11.31M-$10.93MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable-5773.7%-509.4%40.6%-338.1%
FCF marginUnavailableUnavailableUnavailableUnavailable-6017.5%-481.3%-41.0%Unavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable560.2%59.2%5.1%Unavailable
Current ratio8.61x15.39x11.33x4.59xUnavailable6.53xUnavailableUnavailable
Revenue YoY growthUnavailable-100.0%-100.0%-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable-510.6%42.3%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable4444.6%474.6%49.0%322.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable7.2%27.1%0.7%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ARTV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-06-30

Difference 216413000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 216413000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.